Compile Data Set for Download or QSAR
Report error Found 220 Enz. Inhib. hit(s) with all data for entry = 8679
TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317880(US9624217, Compound 33 | US10399976, Compound 33 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412666(US10399976, Compound 2 | (S)-N-((5-(ethylsulfonyl)...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317850(US9624217, Compound 3 | US10399976, Compound 3 | U...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317851(US9624217, Compound 4 | US10399976, Compound 4 | U...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317852(US9624217, Compound 5 | US10399976, Compound 5 | U...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317864(US9624217, Compound 17 | US10399976, Compound 17 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317849(US9624217, Compound 2 | (S)-N-((5-(ethylsulfonyl)...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317869(US9624217, Compound 22 | US10399976, Compound 22 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317875(US9624217, Compound 28 | US10399976, Compound 28 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317876(US9624217, Compound 29 | US10399976, Compound 29 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317877(US9624217, Compound 30 | US10399976, Compound 30 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317878(US9624217, Compound 31 | US10399976, Compound 31 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317880(US9624217, Compound 33 | US10399976, Compound 33 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317881(US9624217, Compound 34 | US10399976, Compound 34 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317886(US9624217, Compound 39 | US10399976, Compound 39 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317892(US9624217, Compound 45 | US10399976, Compound 45 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317896(US9624217, Compound 49 | US10399976, Compound 49 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317901(US9624217, Compound 54 | US10399976, Compound 54 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317902(US9624217, Compound 55 | US10399976, Compound 55 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317904(US9624217, Compound 57 | US10399976, Compound 57 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317905(US9624217, Compound 58 | US10399976, Compound 58 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317906(US9624217, Compound 59 | US10399976, Compound 59 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317914(US9624217, Compound 67 | US10399976, Compound 67 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317988(US9624217, Compound 141 | US10399976, Compound 141...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317989(US9624217, Compound 142 | US10399976, Compound 142...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317991(US9624217, Compound 144 | US10399976, Compound 144...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317854(US9624217, Compound 7 | US10399976, Compound 7 | U...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317881(US9624217, Compound 34 | US10399976, Compound 34 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317868(US9624217, Compound 21 | US10399976, Compound 21 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317874(US9624217, Compound 27 | US10399976, Compound 27 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317879(US9624217, Compound 32 | US10399976, Compound 32 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317882(US9624217, Compound 35 | US10399976, Compound 35 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317885(US9624217, Compound 38 | US10399976, Compound 38 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317891(US9624217, Compound 44 | US10399976, Compound 44 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317894(US9624217, Compound 47 | US10399976, Compound 47 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317898(US9624217, Compound 51 | US10399976, Compound 51 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317899(US9624217, Compound 52 | US10399976, Compound 52 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317903(US9624217, Compound 56 | US10399976, Compound 56 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317910(US9624217, Compound 63 | US10399976, Compound 63 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317911(US9624217, Compound 64 | US10399976, Compound 64 |...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412797(US10399976, Compound 133)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317986(US9624217, Compound 139 | US10399976, Compound 139...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317990(US9624217, Compound 143 | US10399976, Compound 143...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317996(US9624217, Compound 149 | US10399976, Compound 149...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM318006(US9624217, Compound 159 | US10399976, Compound 159...)
Affinity DataIC50: 550nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412670(US10399976, Compound 6 | (S)-N-(4-(ethylsulfonyl)b...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317855(US9624217, Compound 8 | US10399976, Compound 8 | U...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317857(US9624217, Compound 10 | US10399976, Compound 10 |...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317858(US9624217, Compound 11 | US10399976, Compound 11 |...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317859(US9624217, Compound 12 | US10399976, Compound 12 |...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 220 total ) | Next | Last >>
Jump to: